An independent peptide reference — no sellers, every claim sourced

Neuroxelin

Also known as Neuroxelin blend, Neuroxelin 48 mg

Vendor-named cognitive injectable sold as a 48 mg vial; its actual peptide composition is not disclosed anywhere.

preclinical Blends & stacks research chemical

At a glance

Category
Blends & stacks
Status
research chemical
Route
sold as a reconstitutable injectable (subcutaneous) 48 mg vial
Half-life
Not established. No half-life can be given for a product whose contents are undisclosed.

Not a medicine and not approved anywhere. 'Neuroxelin' is a seller's product name, not a pharmacological designation. It is offered as a single 48 mg vial with a reconstitution and dosing guide and is marketed for neuroprotection and cognitive recovery. Crucially, no source found — vendor or independent — states which peptides the vial contains or in what amounts. Dosing-protocol pages that list it place it alongside neuro peptides such as Semax, Selank, PE-22-28 and Pinealon, but present these as comparisons only and do not identify them as its ingredients. Sold as grey-market material 'for research use only', with identity, purity and sterility uncontrolled.

This is a short entry. There is little or no published research on this compound, so there is correspondingly little to report. Empty dosing or reconstitution sections mean no credible figures exist — not that they were left out.

Mechanism of action

Neuroxelin has no mechanism that can be described, because its composition is not published. A blend is only as intelligible as the list of what is in it, and here that list is missing: the vendor material names a total mass (48 mg) and a marketing target (cognition, neuroprotection) but not the peptides themselves.

The product name and the neuro peptides it is listed beside — Semax, Selank, PE-22-28, Pinealon — suggest it is meant to sit in the nootropic-peptide space, where components are proposed to act on ACTH- and tuftsin-derived signalling, BDNF expression and related pathways. That is context, not composition. Attaching any specific mechanism to Neuroxelin would mean guessing at its contents, which this entry will not do.

What the research shows

There is no research on Neuroxelin, and none is possible to assess, because the blend's contents are undisclosed. No study of any design used a product under this name, and without knowing what is in the vial the component literatures cannot even be assembled into an indirect case.

Research in humans

No published human study of Neuroxelin. Because the composition is not stated, it is not possible to say which components' — if any — human data would be relevant.

Animal and lab research

No animal study of Neuroxelin could be located, and none of the neuro peptides it is marketed near can be assigned to it as an ingredient.

Caveats. The central limitation is that the composition is vendor-declared as a name and a total mass only, and is not independently verified — indeed not even itemised by the sellers found. A 48 mg total is large for a cognitive peptide vial, which makes the missing per-component breakdown more consequential rather than less. Everything downstream of composition — mechanism, dosing, a reconstitution calculation, a safety profile — is therefore undefined.

What it is used for

  • Marketed for cognition, focus and memory
  • Marketed for neuroprotection and 'cognitive recovery'
  • No use has been tested for this product, and none can be tied to specific ingredients because the composition is not disclosed

Dosing

  • There is no established dose, and no credible dose can be given. Vendors supply a volume-based protocol for reconstituting the 48 mg vial, but a volume is meaningless without knowing which peptides it delivers and in what proportion.
  • Assembling a dosing schedule for an undisclosed mixture would be inventing one. Where the composition is unknown, the honest field is empty.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Safety

Side effects

  • Cannot be characterised, because the composition is undisclosed
  • General risks of any unregulated injectable apply: injection site reactions, and the possibility of contaminants, endotoxin or non-sterile preparation in grey-market material
  • The absence of a reported side-effect profile here reflects missing information about the contents, not a favourable safety record

Do not use if

  • Any use of a product whose contents are not disclosed — a reader cannot check for a component they should avoid, cannot anticipate an interaction, and cannot attribute a reaction
  • Pregnancy and breastfeeding: no data
  • Children and adolescents: no data
  • Competitive athletes under the WADA code: a blend of undisclosed composition cannot be cleared for competition, since it may contain prohibited substances without the athlete's knowledge

Interactions

Cannot be assessed. Interactions depend on the specific peptides present, and Neuroxelin's contents are not disclosed. No interaction data exist for the product.

Sources

No independently published, peer-reviewed studies were found for this compound. The figures that circulate about it come from supplier dossiers and have not been externally verified. Nothing has been added here from sources of doubtful provenance.